efficacy – Asian Pacific Journal of Allergy and Immunology

April 23, 2023

Efficacy and safety of low- and high-dose slow oral egg immunotherapy for hen’s egg allergy: Single-center non-inferiority randomized trial

Low-dose oral immunotherapy (OIT) is a safe treatment for hen’s egg allergy; however, comparison of its therapeutic effects with those of high-dose OIT has not been reported.

efficacy, Egg allergy, oral immunotherapy, safety

October 25, 2022

House dust mite allergen immunotherapy for monosensitized versus polysensitized patients with allergic rhinitis: A systematic review and meta-analysis

Most patients with allergic rhinitis are polysensitized. The efficacy of house dust mite (HDM) allergen immunotherapy (AIT) compared between monosensitized and polysensitized patients remains limited.

Allergen immunotherapy, Allergic rhinitis, effectiveness, efficacy, house dust mite, monosensitized, polysensitized, subcutaneous immunotherapy, Sublingual immunotherapy

March 14, 2022

Maintained disease control and steroid-sparing effect of subcutaneous immunotherapy in allergic rhinitis and asthma

Allergen immunotherapy is the only currently available treatment strategy that modifies the immune response to the causative allergen and induces clinical improvement and a steroid-sparing effect.

Allergen immunotherapy, Allergic rhinitis, Asthma, efficacy, inhaled steroid, intranasal steroid, steroid sparing

March 14, 2022

As-needed versus regular intranasal corticosteroid for allergic rhinitis: A systematic review and meta-analysis

Daily intranasal corticosteroid (INCS) is recommended for treating allergic rhinitis (AR). Nevertheless, patients are generally not adherent and use it on-demand. The data on the efficacy of as-needed INCS was insufficient.

Allergic rhinitis, as-needed, efficacy, intranasal corticosteroid, on-demand, regular, self-adjusted

January 30, 2021

Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data

Omalizumab is a safe and effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU) but is insufficient in one-third of patients. For serious cases in which omalizumab is ineffective, cyclosporine or methotrexate may be preferred. Most drug trials in CSU have focused on omalizumab or cyclosporine monotherapy.

chronic spontaneous urticaria, cyclosporine, efficacy, methotrexate, Omalizumab, safety, treatment

July 13, 2020

Efficacy, patients’ perception, and cost of medication in allergic rhinitis with subcutaneous immunotherapy

Allergic rhinitis (AR) is the allergic inflammation of nasal mucosa. Treatment of AR includes pharmacotherapy and allergen immunotherapy. Subcutaneous immunotherapy (SCIT) is indicated in inadequate disease control, patient’s preference, or impossible allergen avoidance. SCIT is an effective treatment but its cost is comparatively high. Efficacy, patient perception, and cost of medication are rarely explored in Asia.

cost-benefit, efficacy, Immunotherapy, perception, safety